PROCEPT (PRCT) Director Amy M. Dodrill Receives RSU & Option Awards

What Happened

• Amy M. Dodrill, a director of PROCEPT BioRobotics (PRCT), received equity awards on June 9, 2026: 3,315 restricted stock units (RSUs) and a derivative stock option award covering 5,853 shares. Both awards are reported at $0.00 (no cash paid at grant).
• Total potential equity awarded equals 9,168 shares. These are grants/awards (not sales or open-market purchases) and therefore are compensation/retention-type awards rather than liquidity events.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (appears timely; Form 4s are generally due within two business days).
• Reported amounts/prices: 3,315 RSUs @ $0.00; 5,853 derivative/option units @ $0.00.
• Shares owned after transaction: not specified in this Form 4 filing.
• Footnotes:
  • F1: The 3,315 securities are RSUs; each RSU converts to one share and will vest in full on the earlier of (i) one year after grant or (ii) the next annual meeting, subject to continued service.
  • F2: The 5,853 award is a stock option granted June 9, 2026, with the same vesting trigger (earlier of one-year anniversary or next annual meeting), subject to continued service.
• Filing timeliness: Filed one day after the transaction date; no late-filing indication in the record.

Context

• RSUs represent a contingent right to receive shares if vesting conditions are met; the option award is a derivative grant (not an exercise) and does not create immediate share ownership until exercised or settled.
• Such grants are common as compensation or retention for directors and do not in themselves signal buying or selling intent.